RedHill Biopharma (RDHL) Reports Q4 Operating Loss of $20.7M

RedHill Biopharma (NASDAQ: RDHL) reported Q4 operating loss of $20.7 million. Revenue for the quarter came in at $22.1 million versus the consensus estimate of $24.08 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Independent Bank receives regulatory approval for HCB Financial acquisition
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital